• Sandoz outlines European antibiotic manufacturing expansion cphi-online
    May 20, 2021
    Novartis generics and biosimilars division will invest €150 million during the next 3-5 years at its Kundl, Austria and Palafolls, Spain sites while phasing out production of oral APIs at Les Franqueses site
PharmaSources Customer Service